Charlotta Nilsson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: MICROBIAL CELL FACTORIES. 2024;23(1):39
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9
Ninyio N; Schmitt K; Sergon G; Nilsson C; Andersson S; Scherbak N
Article: PLOS ONE. 2024;19(2):e0298912
Laboratory-based evaluation of the 4th-generation Alere™ HIV Combo rapid point-of-care test
Manjate A; Nilsson C; Axelsson M; Lindroth S; Sirbu D; Sacarlal J; Andersson S; Unemo M
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2022;91(5):439-448
The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers-A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania
Faini D; Msafiri F; Munseri P; Bakari M; Lyamuya E; Sandstrom E; Biberfeld G; Nilsson C; Hanson C; Aboud S
Article: VACCINES. 2022;10(7):1062
Vaccine-Induced Seroreactivity Impacts the Accuracy of HIV Testing Algorithms in Sub-Saharan Africa: An Exploratory Study
Msafiri F; Manjate A; Lindroth S; Tembe N; Chissumba RM; Cumbane V; Jani I; Aboud S; Lyamuya E; Andersson S; Nilsson C
Article: VACCINES. 2022;10(3):359
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingstrom J; Gordon M; Aberg M; Thalin C
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:1075606
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
Horvath A; Rogers L; Pollakis G; Baranov O; Pieroth N; Joseph S; Chachage M; Heitzer A; Maganga L; Msafiri F; Joachim A; Viegas E; Eller L-A; Kibuuka H; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Dhitavat J; Premsri N; Fidler S; Shattock RJJ; Robb ML; Weber J; McCormack S; Munseri PJ; Lyamuya E; Nilsson C; Kroidl A; Hoelscher M; Wagner R; Geldmacher C; Held K
Article: SCIENTIFIC REPORTS. 2021;11(1):7614
Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers
Lagerqvist N; Maleki KT; Verner-Carlsson J; Olausson M; Dillner J; Bystrom JW; Monsen T; Forsell M; Eriksson J; Bogdanovic G; Muschiol S; Ljunggren J; Repo J; Kjerstadius T; Muradrasoli S; Brytting M; Bjorndal AS; Akerlund T; Nilsson C; Klingstrom J
Article: VACCINES. 2020;8(4):E681-681
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
Joachim A; Msafiri F; Onkar S; Munseri P; Aboud S; Lyamuya EF; Bakari M; Billings E; Robb ML; Wahren B; Mhalu FS; Sandstrom E; Rao M; Nilsson C; Biberfeld G
Article: MICROORGANISMS. 2020;8(11):E1722-1722
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
Msafiri F; Joachim A; Held K; Nadai Y; Chissumba RM; Geldmacher C; Aboud S; Stohr W; Viegas E; Kroidl A; Bakari M; Munseri PJ; Wahren B; Sandstrom E; Robb ML; McCormack S; Joseph S; Jani I; Ferrari G; Rao M; Biberfeld G; Lyamuya E; Nilsson C
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:719
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Article: IMMUNOBIOLOGY. 2018;223(12):792-801
Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses
Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018;34(2):193-205
Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandstrom E
Article: PLOS ONE. 2018;13(11):e0206838
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stohr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandstrom E; Lyamuya E
Article: JOURNAL OF VIROLOGY. 2017;91(18):e00730-e00717
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandstrom E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2017;33(8):880-888
Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers
Joachim A; Munseri PJ; Nilsson C; Bakari M; Aboud S; Lyamuya EF; Tecleab T; Liakina V; Scarlatti G; Robb ML; Earl PL; Moss B; Wahren B; Mhalu F; Ferrari G; Sandstrom E; Biberfeld G
Article: BMJ OPEN. 2017;7(7):e015653
Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique
Omar VE; Orvalho A; Nalia I; Kaliff M; Lillsunde-Larsson G; Ramqvist T; Nilsson C; Falk K; Nafissa O; Vindorai JI; Andersson S
Article: HELIYON. 2017;3(6):e00339
HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.
Hinkula J; Petkov S; Ljungberg K; Hallengärd D; Bråve A; Isaguliants M; Falkeborn T; Sharma S; Liakina V; Robb M; Eller M; Moss B; Biberfeld G; Sandström E; Nilsson C; Markland K; Blomberg P; Wahren B
Article: PLOS ONE. 2016;11(5):e0155702
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandstrom E; Kroidl A; Bakari M; Nilsson C; McCormack S
Article: PLOS ONE. 2015;10(6):e0131748
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Brove A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandstrom E; Wahren B
Article: PLOS ONE. 2015;10(4):e0119629
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
Munseri PJ; Kroidl A; Nilsson C; Joachim A; Geldmacher C; Mann P; Moshiro C; Aboud S; Lyamuya E; Maboko L; Missanga M; Kaluwa B; Mfinanga S; Podola L; Bauer A; Godoy-Ramirez K; Marovich M; Moss B; Hoelscher M; Gotch F; Stoehr W; Stout R; McCormack S; Wahren B; Mhalu F; Robb ML; Biberfeld G; Sandstrom E; Bakari M
Article: PLOS ONE. 2015;10(4):e0118486
Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandstrom E; Biberfeld G; Ferrari G; Polonis VR
Article: PLOS ONE. 2015;10(3):e0121452
Incidence of HIV and the Prevalence of HIV, Hepatitis B and Syphilis among Youths in Maputo, Mozambique: A Cohort Study
Viegas EO; Tembe N; Macovela E; Goncalves E; Augusto O; Ismael N; Sitoe N; De Schacht C; Bhatt N; Meggi B; Araujo C; Sandstrom E; Biberfeld G; Nilsson C; Andersson S; Jani I; Osman N
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2014;21(3):391-398
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
Penezina O; Krueger NX; Rodriguez-Chavez IR; Busch MP; Hural J; Kim JH; O'Connell RJ; Hunter E; Aboud S; Higgins K; Kovalenko V; Clapham D; Crane D; Levin AE; HIV Selectest Study Group
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30(3):299-311
Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees
Nilsson C; Godoy-Ramirez K; Hejdeman B; Brave A; Gudmundsdotter L; Hallengard D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandstrom E; Wahren B; Biberfeld G
Article: PLOS ONE. 2014;9(5):e97391
Reference Values for Clinical Laboratory Parameters in Young Adults in Maputo, Mozambique
Tembe N; Joaquim O; Alfai E; Sitoe N; Viegas E; Macovela E; Goncalves E; Osman N; Andersson S; Jani I; Nilsson C
Article: AIDS. 2012;26(18):2275-2284
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism
Marcelino JM; Borrego P; Nilsson C; Familia C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
Article: VACCINE. 2011;29(46):8417-8428
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Brave A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandstrom E
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2010;17(7):1124-1131
Strong HIV-Specific CD4⁺ and CD8⁺ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes
Aboud S; Nilsson C; Karlen K; Marovich M; Wahren B; Sandstrom E; Gaines H; Biberfeld G; Godoy-Ramirez K
Article: JOURNAL OF MEDICAL VIROLOGY. 2009;81(12):1991-1998
Comparison of the Performance of Rapid HIV Tests Using Samples Collected for Surveillance in Mozambique
Melo J; Nilsson C; Mondlane J; Osman N; Biberfeld G; Folgosa E; Andersson S
Article: VACCINE. 2009;27(33):4468-4474
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
Gudmundsdotter L; Nilsson C; Brave A; Hejdeman B; Earl P; Moss B; Robb M; Cox J; Michael N; Marovich M; Biberfeld G; Sandstrom E; Wahren B
Article: AIDS. 2008;22(17):2257-2265
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression
Marcelino JM; Nilsson C; Barroso H; Gomes P; Borrego P; Maltez F; Rosado L; Doroana M; Antunes F; Taveira N
Article: VIROLOGY JOURNAL. 2008;5:96
HIV-2 neutralization by intact V3-specific Fab fragments
Sourial S; Nilsson C
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2008;15(4):585-589
Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects
Nilsson C; Aboud S; Karlen K; Hejdeman B; Urassa W; Biberfeld G
Article: CURRENT HIV RESEARCH. 2006;4(2):229-237
Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125
Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
Article: MOLECULAR BIOTECHNOLOGY. 2005;30(2):155-162
Cloning, expression, and purification of HIV-2 gp125
Sourial S; Wärnmark A; Nilsson C; Björling E; Achour A; Harris RA
Article: JOURNAL OF GENERAL VIROLOGY. 2004;85(Pt 8):2407-2419
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
Mäkitalo B; Lundholm P; Hinkula J; Nilsson C; Karlén K; Mörner A; Sutter G; Erfle V; Heeney JL; Wahren B; Biberfeld G; Thorstensson R
Article: JOURNAL OF VIROLOGY. 2004;78(13):7016-7022
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals
Qin LZ; Nilsson C; Sourial S; Andersson S; Larsen O; Aaby P; Ehnlund M; Björling E
Article: JOURNAL OF MEDICAL PRIMATOLOGY. 2004;33(1):16-24
Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques
Söderlund J; Nilsson C; Loré K; Castanos-Velez E; Ekman M; Heiden T; Biberfeld G; Andersson J; Biberfeld P
Article: VIROLOGY. 2003;308(2):225-232
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
Qin LZ; Skott P; Sourial S; Nilsson C; Andersson S; Ehnlund M; Taveira N; Björling E
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;129(1):11-18
Spontaneous production of RANTES and antigen-specific IFN-γ production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge
Ahmed RKS; Mäkitalo B; Karlén K; Nilsson C; Biberfeld G; Thorstensson R
Article: JOURNAL OF GENERAL VIROLOGY. 2002;83(Pt 4):807-818
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques
Nilsson C; Sutter G; Walther-Jallow L; ten Haaft P; Åkerblom L; Heeney J; Erfle V; Böttiger P; Biberfeld G; Thorstensson R
Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 7):1601-1612
Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys
Walther-Jallow L; Nilsson C; Söderlund J; ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
Article: VACCINE. 2001;19(25-26):3526-3536
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
Nilsson C; Mäkitalo B; Berglund P; Bex F; Liljeström P; Sutter G; Erfle V; ten Haaft P; Heeney J; Biberfeld G; Thorstensson R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2001;53(3):245-253
Role of CD8⁺ cell-produced anti-viral factors in protective immunity in HIV-2-exposed but seronegative macaques resistant to intrarectal SIVsm challenge
Ahmed RKS; Nilsson C; Biberfeld G; Thorstensson R
Article: VIROLOGY. 2000;278(2):400-411
Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge
Zuber B; Hinkula J; Vödrös D; Lundholm P; Nilsson C; Mörner A; Levi M; Benthin R; Wahren B
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2000;51(2):186-194
Recruitment of monocyte derived dendritic cells ex vivo from SIV infected and non infected cynomolgus monkeys
Söderlund J; Nilsson C; Ekman M; Walther L; Gaines H; Biberfeld G; Biberfeld P
Article: JOURNAL OF GENERAL VIROLOGY. 1999;80:1569-1574
β-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge
Ahmed RKS; Nilsson C; Wang YF; Lehner T; Biberfeld G; Thorstensson R
Article: AIDS. 1998;12(17):2261-2270
Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm
Nilsson C; Mäkitalo B; Thorstensson R; Norley S; Binninger-Schinzel D; Cranage M; Rud E; Biberfeld G; Putkonen P
Article: NATURE MEDICINE. 1995;1(9):914-918
LONG-TERM PROTECTION AGAINST SIV-INDUCED DISEASE IN MACAQUES VACCINATED WITH A LIVE ATTENUATED HIV-2 VACCINE
PUTKONEN P; WALTHER L; ZHANG YJ; LI SL; NILSSON C; ALBERT J; BIBERFELD P; THORSTENSSON R; BIBERFELD G
Visa fler

Alla övriga publikationer

Corrigendum: MICROBIAL CELL FACTORIES. 2024;23(1):75
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9 (vol 23, 39, 2024)
Ninyio N; Schmitt K; Sergon G; Nilsson C; Andersson S; Scherbak N
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2008;198(10):1482-1490
Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara
Sandstrom E; Nilsson C; Hejdeman B; Brave A; Bratt G; Robb M; Cox J; VanCott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G
Thesis / dissertation: 2001
HIV-2 and SIV vaccine studies in macaques : with emphasis on humoral immune responses
Nilsson, Charlotta

Anställningar

Anknuten till Forskning, Laboratoriemedicin, Karolinska Institutet, 2022-2024

Examina och utbildning

Docent, virologi, Karolinska Institutet, 2015
MEDICINE DOKTORSEXAMEN, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2001

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI